Vantive dialysis solution batches fail endotoxin tests in Himachal
Himachal’s Baddi drug laboratory found two imported Vantive peritoneal dialysis solution batches non-standard, citing endotoxin failures and nine compliance lapses spanning labelling, safety warnings and importer traceability.
What happened
Himachal’s Baddi drug laboratory found two imported Vantive peritoneal dialysis solution batches non-standard after endotoxin test failures, flagging nine
Key facts
- 2 batches
- 9 regulatory violations
- Indian Pharmacopoeia 2022
- September 3 laboratory report
- September 7 state department letter
Why this matters
The endotoxin failures and nine cited compliance lapses create near-term regulatory, recall, remediation and reputational risk for Vantive’s India dialysis business.
What to watch
- CDSCO recall, stop-sale, import-alert or license-suspension notice.
- Publication of affected batch numbers, expiry dates, importer identity and distribution footprint.
- Additional Vantive products or batches failing quality tests in other state laboratories.
- Evidence of patient adverse events, peritonitis complaints or hospital treatment interruptions.
- Extended customs clearance times, stock-out reports or emergency procurement tenders for dialysis solutions.